1. Markham MJ, Wachter K, Agarwal N, Bertagnolli MM, Chang SM, Dale W, et al. Clinical Cancer Advances 2020: Annual report on progress against cancer from the American Society of Clinical oncology. J Clin Oncol. 2020;38(10):1081–101.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
3. Podyacheva EY, Kushnareva EA, Karpov AA, Toropova YG. Analysis of Models of Doxorubicin-Induced Cardiomyopathy in Rats and Mice. A Modern View From the Perspective of the Pathophysiologist and the Clinician. Front Pharmacol. 2021;12(June):1–12.
4. Santos DS dos, Goldenberg RC dos S. Doxorubicin-Induced Cardiotoxicity: From Mechanisms to Development of Efficient Therapy. Cardiotoxicity. 2018;3–24.
5. McGowan JV, Chung R, Maulik A, Piotrowska I, Walker JM, Yellon DM. Anthracycline Chemotherapy and Cardiotoxicity. Cardiovasc Drugs Ther. 2017;31(1):63–75.
6. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: Molecular advances and pharmacologie developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185–229.
7. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012;52(6):1213–25. http://dx.doi.org/10.1016/j.yjmcc.2012.03.006
8. Yoshino J, Baur JA, Imai S ichiro. NAD + Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metab. 2018;27(3):513–28. https://doi.org/10.1016/j.cmet.2017.11.002
9. Xu W, Barrientos T, Mao L, Rockman HA, Sauve AA, Andrews NC. Lethal Cardiomyopathy in Mice Lacking Transferrin Receptor in the Heart. Cell Rep. 2015;13(3):533–45. http://dx.doi.org/10.1016/j.celrep.2015.09.023
10. Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a preiss-handler independent route to NAD+ in fungi and humans. Cell. 2004;117(4):495–502.
11. Dietrich LS, Muniz O, Powanda M. NAD synthesis in animal tissues. J Vitaminol (Kyoto). 1968;14:123–9.
12. Yang Y, Sauve AA. therapy. 2017;1864(12):1787–800.
13. Croft T, Venkatakrishnan P, Lin SJ. Nad+ metabolism and regulation: Lessons from yeast. Biomolecules. 2020;10(2).
14. Xiao W, Wang RS, Handy DE, Loscalzo J. NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism. Antioxidants Redox Signal. 2018;28(3):251–72.
15. Hwang ES, Song SB. Possible adverse effects of high-dose nicotinamide: Mechanisms and safety assessment. Biomolecules. 2020;10(5):1–21.
16. Imai S. Nicotinamide Phosphoribosyltransferase (Nampt): A Link Between NAD Biology, Metabolism, and Diseases. Curr Pharm Des. 2009;15(1):20–8.
17. Yoshino J, Mills KF, Yoon MJ, Imai SI. Nicotinamide mononucleotide, a key NAD + intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528–36.
18. Braidy N, Poljak A, Grant R, Jayasena T, Mansour H, Chan-Ling T, et al. Mapping NAD+ metabolism in the brain of ageing Wistar rats: Potential targets for influencing brain senescence. Biogerontology. 2014;15(2):177–98.
19. Mehmel M, Jovanović N, Spitz U. Nicotinamide riboside—the current state of research and therapeutic uses. Nutrients. 2020;12(6):1–22.
20. Hopp, Grüter, Hottiger. Regulation of Glucose Metabolism by NAD+ and ADP-Ribosylation. Cells. 2019;8(8):890.
21. Ratajczak J, Joffraud M, Trammell SAJ, Ras R, Canela N, Boutant M, et al. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nat Commun. 2016;7:1–12.
22. Tempel W, Rabeh WM, Bogan KL, Belenky P, Wojcik M, Seidle HF, et al. Nicotinamide riboside kinase structures reveal new pathways to NAD +. PLoS Biol. 2007;5(10):2220–30.
23. Fletcher. The Emergence of the Nicotinamide Riboside Kinases in the regulation of NAD+ Metabolism. 2018;44(August):1–18.
24. Trammell SAJ, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, et al. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nat Commun. 2016;7:1–14. http://dx.doi.org/10.1038/ncomms12948
25. Bogan KL, Brenner C. Nicotinic acid, nicotinamide, and nicotinamide riboside: A molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr. 2008;28:115–30.
26. Yang T, Chan NYK, Sauve AA. Syntheses of nicotinamide riboside and derivatives: Effective agents for increasing nicotinamide adenine dinucleotide concentrations in mammalian cells. J Med Chem. 2007;50(26):6458–61.
27. Kulikova V, Shabalin K, Nerinovski K, Dölle C, Niere M, Yakimov A, et al. Generation, release, and uptake of the NAD precursor nicotinic acid riboside by human cells. J Biol Chem. 2015;290(45):27124–37.
28. Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nat Rev Mol Cell Biol. 2021;22(2):119–41. http://dx.doi.org/10.1038/s41580-020-00313-x
29. Cantó C, Sauve AA, Bai P. Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes. Mol Aspects Med. 2013;34(6):1168–201.
30. Masri S, Rigor P, Cervantes M, Ceglia N, Sebastian C, Xiao C, et al. Partitioning circadian transcription by SIRT6 leads to segregated control of cellular metabolism. Cell. 2014;158(3):659–72. http://dx.doi.org/10.1016/j.cell.2014.06.050
31. Carrico C, Meyer JG, He W, Gibson BW, Verdin E. The Mitochondrial Acylome Emerges: Proteomics, Regulation by Sirtuins, and Metabolic and Disease Implications. Cell Metab. 2018;27(3):497–512. https://doi.org/10.1016/j.cmet.2018.01.016
32. Jang SY, Kang HT, Hwang ES. Nicotinamide-induced mitophagy: Event mediated by high NAD+/NADH ratio and SIRT1 protein activation. J Biol Chem. 2012;287(23):19304–14.
33. Cantó C, Jiang LQ, Deshmukh AS, Mataki C, Coste A, Lagouge M, et al. Interdependence of AMPK and SIRT1 for Metabolic Adaptation to Fasting and Exercise in Skeletal Muscle. Cell Metab. 2010;11(3):213–9. http://dx.doi.org/10.1016/j.cmet.2010.02.006
34. Cantó C, Menzies KJ, Auwerx J. NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus. Cell Metab. 2015;22(1):31–53.
35. Cantó C, Auwerx J. Targeting sirtuin 1 to improve metabolism: All you need is NAD +? Pharmacol Rev. 2012;64(1):166–87.
36. Jing E, Gesta S, Kahn CR. SIRT2 Regulates Adipocyte Differentiation through FoxO1 Acetylation/Deacetylation. Cell Metab. 2007;6(2):105–14.
37. Rothgiesser KM, Erener S, Waibel S, Lüscher B, Hottiger MO. SIRT2 regulates NF-κB-dependent gene expression through deacetylation of p65 Lys310. J Cell Sci. 2010;123(24):4251–8.
38. Giralt A, Villarroya F. SIRT3, a pivotal actor in mitochondrial functions: Metabolism, cell death and aging. Biochem J. 2012;444(1):1–10.
39. Bordone L, Motta MC, Picard F, Robinson A, Jhala US, Apfeld J, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic β cells. PLoS Biol. 2006;4(2):210–20.
40. Hirschey MD, Shimazu T, Goetzman E, Jing E, Schwer B, Lombard DB, et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature. 2010;464(7285):121–5.
41. Du J, Zhou Y, Su X, Yu JJ, Khan S, Jiang H, et al. Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science (80- ). 2011;334(6057):806–9.
42. Zhong L, D’Urso A, Toiber D, Sebastian C, Henry RE, Vadysirisack DD, et al. The Histone Deacetylase Sirt6 Regulates Glucose Homeostasis via Hif1α. Cell. 2010;140(2):280–93. http://dx.doi.org/10.1016/j.cell.2009.12.041
43. Ford E, Voit R, Liszt G, Magin C, Grummt I, Guarente L. Mammalian Sir2 homolog SIRT7 is an activator of RNA polymerase I transcription. Genes Dev. 2006;20(9):1075–80.
44. Barber MF, Michishita-Kioi E, Xi Y, Tasselli L, Kioi M, Moqtaderi Z, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature. 2012;487(7405):114–8. http://dx.doi.org/10.1038/nature11043
45. Bai P, Cantó C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab. 2012;16(3):290–5.
46. Scheibye-Knudsen M, Mitchell SJ, Fang EF, Iyama T, Ward T, Wang J, et al. A high-fat diet and NAD+ activate sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 2014;20(5):840–55. http://dx.doi.org/10.1016/j.cmet.2014.10.005
47. Bai P, Canto C, Brunyánszki A, Huber A, Szántó M, Cen Y, et al. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab. 2011;13(4):450–60.
48. Boehler C, Gauthier LR, Mortusewicz O, Biard DS, Saliou JM, Bresson A, et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc Natl Acad Sci U S A. 2011;108(7):2783–8.
49. Graeff R, Liu Q, Kriksunov IA, Hao Q, Hon CL. Acidic residues at the active sites of CD38 and ADP-ribosylt cyclase determine nicotinic acid adenine dinucleotide phosphate (NAADP) synthesis and hydrolysis activities. J Biol Chem. 2006;281(39):28951–7.
50. Ortolan E, Augeri S, Fissolo G, Musso I, Funaro A. CD157: From immunoregulatory protein to potential therapeutic target. Immunol Lett. 2019;205(April):59–64. https://doi.org/10.1016/j.imlet.2018.06.007
51. Aksoy P, White TA, Thompson M, Chini EN. Regulation of intracellular levels of NAD: A novel role for CD38. Biochem Biophys Res Commun. 2006;345(4):1386–92.
52. Escande C, Nin V, Price NL, Capellini V, Gomes AP, Barbosa MT, et al. Flavonoid apigenin is an inhibitor of the NAD+ase CD38: Implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes. 2013;62(4):1084–93.
53. Shubinsky G, Schlesinger M. The CD38 lymphocyte differentiation marker: New insight into its ectoenzymatic activity and its role as a signal transducer. Immunity. 1997;7(3):315–24.
54. Quarona V, Zaccarello G, Chillemi A, Brunetti E, Singh VK, Ferrero E, et al. CD38 and CD157: A long journey from activation markers to multifunctional molecules. Cytom Part B - Clin Cytom. 2013;84(4):207–17.
55. Deaglio S, Morra M, Mallone R, Ausiello CM, Prager E, Garbarino G, et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J Immunol. 1998;160(1):395–402. http://www.ncbi.nlm.nih.gov/pubmed/9551996
56. Deaglio S, Aydin S, Grand MM, Vaisitti T, Bergui L, D’Arena G, et al. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol Med. 2010;16(3–4):87–91.
57. Wang Q, Zhang S, Liu T, Wang H, Liu K, Wang Q, et al. Sarm1/Myd88-5 Regulates Neuronal Intrinsic Immune Response to Traumatic Axonal Injuries. Cell Rep. 2018;23(3):716–24. https://doi.org/10.1016/j.celrep.2018.03.071
58. Lee HC, Zhao YJ. Resolving the topological enigma in Ca2+ signaling by cyclic ADP-ribose and NAADP. J Biol Chem. 2019;294(52):19831–43.
59. Carty M, Bowie AG. SARM: From immune regulator to cell executioner. Biochem Pharmacol. 2019;161(December 2018):52–62. https://doi.org/10.1016/j.bcp.2019.01.005
60. Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Poljak A, Grant R. Age related changes in NAD+ metabolism oxidative stress and sirt1 activity in wistar rats. PLoS One. 2011;6(4):1–18.
61. Gomes AP, Price NL, Ling AJY, Moslehi JJ, Montgomery MK, Rajman L, et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell. 2013;155(7):1624–38.
62. Ramsey KM, Mills KF, Satoh A, Imai SI. Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice. Aging Cell. 2008;7(1):78–88.
63. Cantó C, Gerhart-Hines Z, Feige JN, Lagouge M, Noriega L, Milne JC, et al. AMPK regulates energy expenditure by modulating NAD + metabolism and SIRT1 activity. Nature. 2009;458(7241):1056–60.
64. Chen D, Bruno J, Easlon E, Lin SJ, Cheng HL, Alt FW, et al. Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev. 2008;22(13):1753–7.
65. Cerutti R, Pirinen E, Lamperti C, Marchet S, Sauve AA, Li W, et al. NAD+-dependent activation of Sirt1 corrects the phenotype in a mouse model of mitochondrial disease. Cell Metab. 2014;19(6):1042–9.
66. Khan NA, Auranen M, Paetau I, Pirinen E, Euro L, Forsström S, et al. Effective treatment of mitochondrial myopathy by nicotinamide riboside, a vitamin B3. EMBO Mol Med. 2014;6(6):721–31.
67. Imai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends Cell Biol. 2014;24(8):464–71.
68. Kaelin WG, McKnight SL. Influence of metabolism on epigenetics and disease. Cell. 2013;153(1):56–69. http://dx.doi.org/10.1016/j.cell.2013.03.004
69. Cantó C, Houtkooper RH, Pirinen E, Youn DY, Oosterveer MH, Cen Y, et al. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 2012;15(6):838–47.
70. Brown KD, Maqsood S, Huang J, Pan Y, Harkcom W, Li W, et al. Brown, Jaffrey 2014 Activation of SIRT3 by the NAD+ precursor nicotinamide riboside protects from noise-induced hearing loss.pdf. 2016;20(6):1059–68.
71. Frederick DW, Loro E, Liu L, Davila A, Chellappa K, Silverman IM, et al. Loss of NAD Homeostasis Leads to Progressive and Reversible Degeneration of Skeletal Muscle. Cell Metab. 2016;24(2):269–82. http://dx.doi.org/10.1016/j.cmet.2016.07.005
72. Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P, et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science (80- ). 2016;352(6292):1436–43.
73. Gong B, Pan Y, Vempati P, Zhao W, Knable L, Ho L, et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol Aging. 2013;34(6):1581–8. Available from: http://dx.doi.org/10.1016/j.neurobiolaging.2012.12.005
74. Trammell SAJ, Brenner C. Targeted, LCMS-based metabolomics for quantitative measurement of NAD+ metabolites. Comput Struct Biotechnol J. 2013;4(5):e201301012. http://dx.doi.org/10.5936/csbj.201301012
75. Trammell SAJ, Weidemann BJ, Chadda A, Yorek MS, Holmes A, Coppey LJ, et al. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci Rep. 2016;6(May):1–7. http://dx.doi.org/10.1038/srep26933
76. Trammell SAJ, Y. L, Redpath P, Migaud ME, Brenner C. Nicotinamide riboside is a major NAD+ precursor vitamin in cow milk. J Nutr. 2016;146(5):957–63.
77. Hong G, Zheng D, Zhang L, Ni R, Wang G, Fan GC, et al. Administration of nicotinamide riboside prevents oxidative stress and organ injury in sepsis. Free Radic Biol Med. 2018;123:125–37. https://doi.org/10.1016/j.freeradbiomed.2018.05.073
78. Zheng D, Zhang Y, Zheng M, Cao T, Wang G, Zhang L, et al. HHS Public Access. 2019;133(13):1505–21.
79. Zhang X, Henneman NF, Girardot PE, Sellers JT, Chrenek MA, Li Y, et al. Systemic Treatment with Nicotinamide Riboside Is Protective in a Mouse Model of Light-Induced Retinal Degeneration. Investig Ophthalmol Vis Sci. 2020;61(10).
80. Conze DB, Crespo-Barreto J, Kruger CL. Safety assessment of nicotinamide riboside, a form of Vitamin B3. Hum Exp Toxicol. 2016;35(11):1149–60.
81. Kourtzidis IA, Stoupas AT, Gioris IS, Veskoukis AS, Margaritelis N V., Tsantarliotou M, et al. The NAD+ precursor nicotinamide riboside decreases exercise performance in rats. J Int Soc Sports Nutr. 2016;13(1):1–4. http://dx.doi.org/10.1186/s12970-016-0143-x
82. Kourtzidis IA, Dolopikou CF, Tsiftsis AN, Margaritelis N V., Theodorou AA, Zervos IA, et al. Nicotinamide riboside supplementation dysregulates redox and energy metabolism in rats: Implications for exercise performance. Exp Physiol. 2018;103(10):1357–66.
83. Hamity M V., White SR, Walder RY, Schmidt MS, Brenner C, Hammond DL. Nicotinamide riboside, a form of vitamin B3 and NAD + precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats. Pain. 2017;158(5):962–72.
84. Toropova YG, Pechnikova NA, Zelinskaya IA, Zhuravsky SG, Kornyushin O V., Gonchar AI, et al. Nicotinamide riboside has protective effects in a rat model of mesenteric ischaemia-reperfusion. Int J Exp Pathol. 2018;99(6):304–11.
85. Módis K, Gerö D, Erdélyi K, Szoleczky P, Dewitt D, Szabo C. Cellular bioenergetics is regulated by PARP1 under resting conditions and during oxidative stress. Biochem Pharmacol. 2012;83(5):633–43.
86. Brunet A, Sweeney LB, Sturgill JF, Chua KF, Greer PL, Lin Y, et al. Stress-Dependent Regulation of FOXO Transcription Factors by the SIRT1 Deacetylase. Science (80- ). 2004;303(5666):2011–5.
87. Han MK, Song EK, Guo Y, Ou X, Mantel C, Broxmeyer HE. SIRT1 Regulates Apoptosis and Nanog Expression in Mouse Embryonic Stem Cells by Controlling p53 Subcellular Localization. Cell Stem Cell. 2008;2(3):241–51.
88. Brookins Danz ED, Skramsted J, Henry N, Bennett JA, Keller RS. Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med. 2009;46(12):1589–97. http://dx.doi.org/10.1016/j.freeradbiomed.2009.03.011
89. Alcendor RR, Gao S, Zhai P, Zablocki D, Holle E, Yu X, et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res. 2007;100(10):1512–21.
90. Hsu CP, Yamamoto T, Oka S, Sadoshima J. The function of nicotinamide phosphoribosyltransferase in the heart. DNA Repair (Amst). 2014;23:64–8. http://dx.doi.org/10.1016/j.dnarep.2014.08.005
91. Diguet N, Trammell SAJ, Tannous C, Deloux R, Piquereau J, Mougenot N, et al. Nicotinamide riboside preserves cardiac function in a mouse model of dilated cardiomyopathy. Circulation. 2018;137(21):2256–73.
92. Luo M, Anderson ME. Mechanisms of altered Ca2+ handling in heart failure. Circ Res. 2013;113(6):690–708.
93. Luu AZ, Chowdhury B, Al-Omran M, Teoh H, Hess DA, Verma S. Role of Endothelium in Doxorubicin-Induced Cardiomyopathy. JACC Basic to Transl Sci. 2018;3(6):861–70.
94. Mateuszuk Ł, Campagna R, Kutryb-Zając B, Kuś K, Słominska EM, Smolenski RT, et al. Reversal of endothelial dysfunction by nicotinamide mononucleotide via extracellular conversion to nicotinamide riboside. Biochem Pharmacol. 2020;178(December 2019):114019. https://doi.org/10.1016/j.bcp.2020.114019
95. Westman EL, Canova MJ, Radhi IJ, Koteva K, Kireeva I, Waglechner N, et al. Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012;19(10):1255–64. http://dx.doi.org/10.1016/j.chembiol.2012.08.011
96. Ma W, Mao Q, Xia W, Dong G, Yu C, Jiang F. Gut microbiota shapes the efficiency of cancer therapy. Front Microbiol. 2019;10(JUN).